Sionna Therapeutics, Inc. Common Stock (SION) Stock Price
SIONStock
$5.87−77.18%52W
Market Cap$265.03M
P/E—
PEG Ratio—
Div yield—
Beta1.39
SION Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-96.20%
Price vs S&P 500 (4W)-89.63%
VGM Score19.78
SION Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.65 | -$0.66 | -1.99%(-$0.01) | |
| Q1 2026 | -$0.50 | -$0.60 | -19.11%(-$0.10) | |
| Q4 2025 | -$0.54 | -$0.46 | +14.02%(+$0.08) | |
| Q3 2025 | -$0.47 | -$0.46 | +3.16%(+$0.01) | |
| Q2 2025 | -$0.45 | -$0.41 | +9.56%(+$0.04) |
SION Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.18
4.18
4.18
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SIONSionna Therapeutics, Inc. Common Stock | — | — | F | $5.87 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Sionna Therapeutics, Inc. Common Stock
Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for cystic fibrosis (CF), a progressive genetic disorder caused by mutations in the CFTR gene. The company's approach targets the disease mechanism by normalizing CFTR protein function to deliver clinically meaningful benefits. The company is entirely focused on CF drug development.